Abstract: Osteopontin (OPN) is a glycophosphoprotein expressed by several cell types and has pro-adhesive, chemotactic, and cytokine-like properties. OPN is involved in a number of physiologic and pathologic events including angiogenesis, apoptosis, inflammation, oxidative stress, remyelination, wound healing, bone remodeling, cell migration and tumorigenesis. Since these functions of OPN, and the events that it regulates, are involved with neurodegeneration, we examined whether OPN was differentially expressed in the hippocampus of the Alzheimer's disease (AD) compared with agematched (59-93 years) control brain. We report for the first time the immunocytochemical localization of OPN in the cytoplasm of pyramidal neurons. In AD brains, there was a significant 41 % increase in the expression of neuron OPN compared with age-matched control brain. No staining of other neuronal cell types was observed. Additionally, there was a significant positive correlation between OPN staining intensity and both amyloid-load (r 2 = 0.25; P < 0.05; n = 20) and aging (r 2 = 0.32; P < 0.01; n = 20) among all control and AD subjects. Controlling for age indicated that OPN expression was significantly influenced by amyloid-load, but not age. While the functional consequences of this amyloid-associated increase in OPN expression are unclear, it is notable that OPN is primarily localized to those neurons that are known to be vulnerable to AD-related neurite loss, degeneration and death. Given that the induction of OPN expression (and amyloid-generation) is associated with remodeling and tumorigenesis, our results suggest that OPN may play a role in the aberrant re-entry of neurons into the cell cycle and/or neuronal remyelination in AD.
INTRODUCTION
Alzheimer's disease (AD) is invariably associated with and defined by neuron death, synapse loss and the presence of extracellular deposits of amyloid (senile plaques) and intracellular neurofibrillary tangles (NFT's) in the brain and cerebral blood vessels [1] . NFT's are composed primarily of highly phosphorylated tau in paired helical filaments while senile plaques are composed primarily of fibrillar amyloid- [2, 3] . Amyloid-is a 39-42 amino acid protein derived from the amyloid-protein precursor (A PP) via proteolytic cleavage at the -and -secretase cleavage sites. Associated with these pathogenic and biochemical changes is a chronic inflammatory response, oxidative stress and altered metal ion metabolism [4] . A central hypothesis that has developed over the last decade that explains the presence of all these bio-*Address correspondence to this author at the University of WisconsinMadison, School of Medicine and Public Health, Wm S. Middleton Memorial VA (GRECC 11G), 2500 Overlook Terrace, Madison, WI 53705, USA; Tel: 608 256-1901, Ext. 11664; Fax: 608 280-7291; E-mail: csa@medicine.wisc.edu chemical and pathological changes in the AD brain is the aberrant re-entry of differentiated neurons into the cell cycle [reviewed in 5, 6] . Identifying factors that regulate the neuron cell cycle is therefore important for our understanding of disease progression.
Osteopontin (OPN) is a negatively charged, acidic, hydrophilic, glycol-phosphoprotein that is constitutively expressed in several cell types (bone, neurons, fibroblasts, endothelial cells, epithelial cells, macrophages, and smooth muscle cells), and that also is expressed and secreted in numerous human cancers. OPN functions in cell adhesion, chemotaxis, macrophage-directed interleukin-10 (IL-10) suppression, stress-dependent angiogenesis, prevention of apoptosis, and anchorage-independent growth of tumor cells by regulating cell-matrix interactions and cellular signaling through binding with integrin and CD44 receptors [7] [8] [9] [10] [11] . Induced expression of OPN has been detected in Tlymphocytes, epidermal cells, bone cells, macrophages, and tumor cells in remodeling processes such as inflammation, ischemia-reperfusion, bone resorption, and tumor progres-sion [11] . OPN expression also is increased in transformed cells, including breast cancer, prostate cancer, osteosarcoma, glioblastoma and squamous cell carcinoma [12, 13] . Recently, substantial evidence has linked OPN with the regulation of metastatic spread by tumor cells. This may reflect inducible expression that is secondary to oncogene transformation [14, 15] . Importantly, transfection of cells with OPN increases their malignant phenotype [16] [17] [18] . That OPN plays a central role in tumorigenesis is strongly supported by studies showing that ras transformation of cells from OPN knockout mice results in impaired colony formation in soft agar and slow tumor growth in vivo compared with wild-type mice [19] . OPN appears to contribute to malignometer through both inhibition of apoptosis and activation of various matrix-degrading proteases.
Given the above actions of OPN in remodeling and tumorigenesis, we assessed whether the expression of OPN was altered in AD brains. We find that OPN expression is increased 41 % in AD compared to age-matched control brain, and that OPN expression is positively correlated with both amyloid-and age. OPN expression was dependent upon amyloid-load but not age. These results suggest that OPN may be upregulated as a result of cell cycle-related changes and/or as a compensatory response to neuronal degeneration in the AD brain.
MATERIALS AND METHODS

Tissue Sections
Hippocampus tissue from pathologically confirmed AD cases (n = 10; ages 59-93, average = 80.7 years; postmortem interval (PMI) 3-13 h, average = 7.89 h) and age-matched controls (n = 10; ages 67-86, average = 77.0 years; PMI 4-27 h, average = 15.2 h) were fixed in methacarn (methanol:chloroform:acetic acid; 6:3:1) overnight at 4° C. Ages and postmortem interval of AD and age-matched controls were not significantly different. All of the AD cases met the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) criteria for AD. The tissue was then embedded in paraffin and cut into 7 m sections that were placed on silane-coated slides (Sigma, St. Louis, MO, USA).
Immunocytochemistry
Paraffin was removed from the tissue sections with xylene and then hydrated though a series of graded ethanol. Endogenous peroxidase activity was eliminated with a 30 min. incubation in 3 % H 2 O 2 in methanol. Following hydration, the sections were rinsed in Tris-buffered saline (TBS; 50 mM Tris-HCl and 150 mM NaCl, pH 7.6) and then treated with 70% formic acid for 5 min. at room temperature. Nonspecific binding sites were blocked by 30 min. incubation with 10 % normal goat serum in TBS prior to primary antibody application. OPN was detected using a mouse monoclonal antibody, Akm2A1 (5 g/mL) [20] . Amyloiddeposition was detected in serial sections using the mouse monoclonal antibody, 4G8 (1:1000; Signet Laboratories, Dalham, MA). The primary antibodies were omitted in serial section controls. Immunostaining was developed by the peroxidase-antiperoxidase procedure [21] using 3-3'-diaminobenzidine (Dako, Glostrup, Denmark) as the cosubstrate.
Immunohistochemical Staining Quantitation
Three adjacent fields of hippocampus were viewed with a Zeiss Axiophot microscope (20x objective; total area 1 mm 2 ) with an attached Zeiss Axiocam digital camera and Zeiss Image Analysis system (KS300). The intensity of the immunoreaction for OPN in each field was determined by measuring the average optical density (OD) of the cytoplasm and nucleus of pyramidal neurons as previously described [22] . The OD for each field was corrected for background by subtracting the OD of an adjacent area that did not contain positive staining. The proportion of amyloid plaques in serial sections also was determined as described above and the relative area of the plaques was calculated and then averaged as previously described [22] .
Statistical Analyses
Students t-test (independent, two-tailed, assuming unequal variances; Statview 5.0; SAS Institute, Inc.) was performed on OPN staining intensity and amyloid-load between control and AD brains to determine statistically significant differences. Simple and partial correlational analyses were conducted between neuronal OPN staining, amyloid load, age, PMI and sex using the Statview 5.0 and SPSS (Version 12.0) statistical programs.
RESULTS
To examine if OPN was expressed in neurons of the hippocampus, and whether there were changes in the expression of this tumorigenic marker during neurodegeneration, hippocampal tissue from AD and age-matched controls was sectioned and stained using the OPN monoclonal antibody Akm2A1. Immunocytochemical analyses indicated OPN immunoreactivity in the cytoplasm of pyramidal neurons in both AD (Fig. 1B) and age-matched control subjects (Fig.  1D) . Quantitative analysis of the CA1 region revealed a significant 41 % increase in the level of OPN in this neuron population in AD compared with age-matched control brains ( Fig. 2A ; p < 0.05; n = 10), an increase that remained significant (p < 0.05) after correcting for age. Stained neurons were apparent throughout the CA1 region of the hippocampus being distributed along the dentate gyrus and throughout the surrounding tissue. Some elderly control brains with significant neurofibrillary pathology showed intermediate levels of neuronal OPN staining (not shown).
To examine if there was an association between amyloiddeposition and OPN expression, serial sections were immunohistochemically stained for amyloid-using the monoclonal antibody 4G8. Extracellular amyloid-deposition was observed throughout the CA1 region of the hippocampus (Fig. 1A) in AD and occasionally in age-matched control brains (Fig. 1C) . Amyloid deposits were typically randomly distributed throughout the tissue, although there was a preferential deposition along the dentate gyrus. Quantitative analysis of the CA1 region revealed a significant 5.4-fold increase in the level of amyloid-in this region of the brain compared with age-matched control brains ( Fig. 2B ; p < 0.05; n = 10), an increase that remained significant (p < 0.05) after controlling for age. No significant correlations were found between amyloid-load and OPN staining intensity among control individuals alone, or among AD individuals alone. However, a statistically significant positive correlation was found between amyloid-load and OPN staining intensity among all control and AD subjects ( Fig. 3A; r 2 = 0.32; P < 0.05, n = 20). This correlation remained significant after controlling for age (r 2 = 0.22; P < 0.05) and PMI (r 2 = 0.25, P < 0.05), suggesting that amyloid-levels influence OPN expression or vice versa independent of age or PMI.
No significant correlations were found for age and OPN staining among control individuals alone, or among AD individuals alone. However, a significant positive correlation was found for age versus OPN staining intensity among all control and AD subjects ( Fig. 3B; 
DISCUSSION
In this study we report for the first time the localization of OPN in the cytoplasm of pyramidal neurons in the human brain. Previous studies in rats indicated that OPN mRNA expression is primarily localized to neurons of the olfactory bulb, cerebellum [23] and to the brainstem of rats, where transcripts are found at higher levels in the pons and the medulla than in the midbrain [24] . More recent studies have shown that OPN mRNA and protein is highly expressed in myelinating Schwann cells (SCs) in uninjured rat nerves and in myelinating SCs in human sural nerves [25] . Axotomy transiently induced OPN expression in the degenerating distal nerve stump of SCs during the first days after injury [25] . Another recent study in rats indicates that OPN expression also is increased in neurons and activated microglia/astrocytes after cryolesioning [26] . We find similar increases in OPN immunoreactivity in the cytoplasm of pyramidal neurons in the brain of individuals affected by AD in comparison to age-matched controls (Figs. 1B & D) . Notably, OPN was concentrated only in those neurons vulnerable to AD-related neurodegeneration (NFT's). Consistent with an earlier report demonstrating increased OPN expression with age in mouse macrophages [27] , we also find an increase in OPN expression with age in neurons. The presence of elevated levels of OPN in the cytoplasm of neurons in individuals with AD and with aging may be due to one or more of the following: 1) increased intracellular OPN expression; 2) decreased intracellular OPN degradation; 3) decreased OPN secretion and/or 4) increased OPN sequestration from extracellular sources. Since OPN immunoreactivity in macrophages, neurons, and astrocytes was shown to disappear by day 14 post-injury in cryolesioned rat brains [26] and to reach low levels by day 14 in SCs following axotomy [25] , our results suggest that increases in OPN expression in neurons with aging and AD is likely a response to the agerelated neurodegeneration of the brain that is accelerated in AD.
Demyelination has been suggested as a contributing factor to the pathology of brain aging and AD [reviewed in 28]. Interestingly, recombinant OPN treatment has been shown to stimulate both myelin basic protein synthesis and myelin sheath formation in mixed cortical cultures from embryonic mouse brain, an in vitro primary culture model of myelination [25, 29] . Thus, given the large synaptic and neuritic loss in the aging and AD brains, the increased expression of OPN may act to upregulate myelination and remyelination during neurodegeneration. That OPN contains an Arg-Gly-Asp (RGD) cell adhesion motif-mediating interactions with several integrins supports the pro-adhesive properties of OPN in remyelination and repair of damaged neurons/neurites.
Pyramidal neurons in the AD brain are associated with cell cycle alterations that can lead to the downstream biochemical and pathological changes associated with AD: tauphosphorylation, amyloid-deposition, inflammation, oxidative stress, and altered metal ion metabolism [reviewed in 6]. Numerous markers of aberrant cell cycle re-entry have been reported in the AD brain [5, 30] . Since the induction of OPN expression is known to be involved in remodeling processes involved with inflammation and tumorigenesis/metastases, and its expression is increased in numerous transformed cells [12, 13] , our results suggest that OPN may play a role in remodeling processes in the AD brain associated with the aberrant re-entry of neurons into the cell cycle. Similarly, amyloid-, which deposits following head injury and was associated with OPN expression (Fig. 3) , is generated when neurons that are aberrantly driven to divide [31] . Given that amyloid-is neurogenic to neuronal stem cells [32] , amyloid-may play a role in tissue repair following injury. Likewise, increases in OPN expression have been shown to inhibit apoptosis, and promote cell proliferation during times of tissue damage and hypoxia, both of which are characteris-tic of AD [33] . OPN induces proliferation of both rat CG-4 and the mouse Oli-neu oligodendrocyte precursor like cell lines in a dose-dependent manner [29] . OPN also has been linked to the proliferation of vascular smooth muscle cells and glomerular mesangial cells subjected to hypoxic conditions [34] as well as promoting angiogenesis following stress and promoting neovascularization [7] .
OPN acts in the recruitment and retention of macrophages and T cells to inflammatory areas [35] . Dermal injection of purified OPN has shown to induce an inflammatory infiltrate while the presence of neutralizing anti-OPN antibodies dramatically decreases the macrophage recruitment. Therefore, increased OPN expression in the AD brain also may play a role in the phagocytic microgliosis observed in the AD brain.
Other functions for OPN in the aging brain might include a role in inflammation and oxidative stress. Increased neuronal OPN expression in the AD brain is consistent with that observed in other inflammatory diseases such as arthritis [36] , and has been postulated to be a response to tissue degeneration [37] . OPN knockout mice display increased renal dysfunction following renal ischemia-reperfusion injury (a model of NO associated damage) compared with normal mice, indicating a protective function for OPN [38] . Interestingly, OPN has been shown to inhibit inducible nitric oxide synthase (iNOS) expression in both primary renal epithelial cells and macrophages [39] . Thus, OPN may function to protect against NO-induced oxidative damage.
In conclusion, the increase in the expression of OPN correlates with age and disease-related neurodegenerative changes. Whether OPN expression is a response to limit the loss of terminally differentiated and irreplaceable neurons [40] , promote neuron regeneration/repair/remodeling and/or one that promotes the re-entry of terminally differentiated neurons into the cell cycle remains to be determined.
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